Taliglucerase alfa (Elelyso)

Elelyso (taliglucerase alfa) is covered only for the FDA‑approved indication of Type 1 Gaucher disease and is explicitly not authorized for other Gaucher types or any off‑label uses. Coverage requires documented deficient β‑glucocerebrosidase activity or a GBA gene mutation, prescription by or consultation with an appropriate specialist (geneticist, endocrinologist, metabolic disorder sub‑specialist, or lysosomal storage disorder specialist), dosing of 60 U/kg IV no more frequently than every 2 weeks, and authorization is limited to one year.

"Treatment of individuals with Type 1 Gaucher disease (FDA‑approved indication)."

Sign up to see full coverage criteria, indications, and limitations.